Latest Breaking News On - Bristol myers squibb company adverse event - Page 1 : comparemela.com

New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis

Following four years of continuous Sotyktu treatment, clinical response was maintained in more than seven out of 10 patients for Psoriasis Area and Severity Index 75 in the POETYK PSO long-term.

'My Psoriasis Doesn't Define Who I Am'

After being diagnosed with moderate to severe plaque psoriasis, this life coach learned how to feel comfortable in her skin again.

'My Psoriasis Doesn't Define Who I Am'

After being diagnosed with moderate to severe plaque psoriasis, this life coach learned how to feel comfortable in her skin again.

Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up t

Clinical response was maintained at 73.2% for Psoriasis Area and Severity Index (PASI) 75 with three years of continuous Sotyktu treatment in the POETYK PSO long-term extension trialSotyktu demonstrated a consistent safety profile with no increases in adverse events or serious adverse events and no emergence of any.

Bristol Myers Squibb: Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis